Here are the 10-Q quarterly reports from Atrium Therapeutics, Inc. (RNA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNA filings page.
Atrium Therapeutics, Inc. is a newly spun‑off, clinical‑stage biotech developing RNA therapeutics targeting cardiomyopathies. For the six months ended June 30, 2026, it generated $22.6 million in collaboration revenue, mainly from a Bristol Myers Squibb milestone, but recorded a net loss of $36.8 million as R&D and G&A spending ramped up post‑separation.
Cash, cash equivalents and short‑term investments totaled $263.9 million, with total assets of $280.5 million and deferred revenue of $42.7 million, providing funding for at least 12 months. The pipeline is led by ATR 1072 for PRKAG2 syndrome (FDA IND cleared, first enrollment expected by end of 2026) and ATR 1086 for PLN cardiomyopathy (IND filing planned in 2027), alongside two earlier cardiology programs.
The company operates as a single segment, continues to recognize revenue under its BMS collaboration, and in August 2026 became entitled to an additional $15.0 million BMS milestone. It remains pre‑commercial and expects continued operating losses as it advances clinical and manufacturing activities and builds public‑company infrastructure.
Atrium Therapeutics, Inc. reported its first quarter as an independent public company focused on RNA therapeutics for cardiomyopathies. Collaboration revenue reached $19.6 million, up sharply from $1.6 million a year earlier, mainly from a $15.0 million milestone under the Bristol Myers Squibb collaboration.
Operating expenses rose to $36.9 million, driven by higher research and development spending of $16.7 million and general and administrative costs of $20.3 million, including significant stock-based compensation linked to the Spin-Off. Atrium recorded a net loss of $16.6 million, or $0.97 per share, versus a $7.4 million loss in the prior-year quarter.
Following its separation from Avidity Biosciences and Spin-Off in February 2026, Atrium was capitalized with about $270.0 million in cash and ended March 31, 2026 with cash and cash equivalents of $267.8 million and total assets of $292.4 million. Management believes this cash will fund operations for at least 12 months and through Phase 1 proof-of-concept for lead candidate ATR 1072 targeting PRKAG2 syndrome, while advancing ATR 1086 for PLN cardiomyopathy and earlier pipeline programs.